Open Access

Temozolomide abrogates the aggressiveness of urothelial carcinoma cells by enhancing senescence and depleting the side population

  • Authors:
    • Na-Yon Kim
    • Sung-Hyun Hwang
    • Yeseul Yang
    • Yongbaek Kim
  • View Affiliations

  • Published online on: October 21, 2021     https://doi.org/10.3892/ol.2021.13106
  • Article Number: 845
  • Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Patients with advanced urothelial carcinoma (UC) generally have poor prognoses due to therapeutic resistance. Furthermore, there are limited treatment options for advanced UC. Therefore, novel or effective chemotherapeutic agents are needed to improve patient survival. The present study was conducted to investigate the effect of temozolomide (TMZ) on UC cells so as to identify a potential method to overcome therapeutic resistance. TMZ is an alkylating agent with a target different from that of other anticancer drugs used to treat UC, such as cisplatin. TMZ enhanced the autophagic response and senescence, which was mediated via the p53 and p21 pathways. Inhibiting the autophagic response using chloroquine synergistically augmented the cytotoxic effect of TMZ on UC cells. TMZ significantly reduced the invasiveness of UC cells. Notably, the abundance of side population fraction was also significantly reduced following TMZ treatment. Considering that side population fraction is known to confer therapeutic resistance, it is noteworthy that the TMZ treatment markedly decreased side population fraction. Altogether, TMZ may have the potential to be applied as a part of an alternative treatment strategy to reduce the malignancy of UC cells.
View References

Related Articles

Journal Cover

December-2021
Volume 22 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kim N, Hwang S, Yang Y and Kim Y: Temozolomide abrogates the aggressiveness of urothelial carcinoma cells by enhancing senescence and depleting the side population. Oncol Lett 22: 845, 2021
APA
Kim, N., Hwang, S., Yang, Y., & Kim, Y. (2021). Temozolomide abrogates the aggressiveness of urothelial carcinoma cells by enhancing senescence and depleting the side population. Oncology Letters, 22, 845. https://doi.org/10.3892/ol.2021.13106
MLA
Kim, N., Hwang, S., Yang, Y., Kim, Y."Temozolomide abrogates the aggressiveness of urothelial carcinoma cells by enhancing senescence and depleting the side population". Oncology Letters 22.6 (2021): 845.
Chicago
Kim, N., Hwang, S., Yang, Y., Kim, Y."Temozolomide abrogates the aggressiveness of urothelial carcinoma cells by enhancing senescence and depleting the side population". Oncology Letters 22, no. 6 (2021): 845. https://doi.org/10.3892/ol.2021.13106